Medtronic (NYSE:MDT) Releases FY 2025 Earnings Guidance

Medtronic (NYSE:MDT) issued an update on its FY 2025 earnings guidance on Saturday morning. The company provided earnings per share (EPS) guidance of 5.400-5.500 for the period, compared to the consensus estimate of 5.440. The company issued revenue guidance of $33.1 billion-$33.6 billion, compared to the consensus revenue estimate of $33.4 billion.

Medtronic Trading Down 0.2 %

Shares of MDT stock opened at $77.95 on Monday. Medtronic has a 12-month low of $68.84 and a 12-month high of $91.00. The company has a market capitalization of $99.95 billion, a P/E ratio of 28.35, a P/E/G ratio of 2.27 and a beta of 0.82. The company has a quick ratio of 1.55, a current ratio of 2.03 and a debt-to-equity ratio of 0.47. The firm has a 50-day moving average price of $81.20 and a 200 day moving average price of $83.19.

Medtronic (NYSE:MDT) last announced its earnings results on Thursday, May 23rd. The medical technology company reported $1.46 earnings per share for the quarter, topping analysts’ consensus estimates of $1.45 by $0.01. Medtronic had a net margin of 11.36% and a return on equity of 13.47%. The company had revenue of $8.59 billion during the quarter, compared to the consensus estimate of $8.44 billion. During the same period in the previous year, the firm posted $1.57 earnings per share. The company’s revenue was up .5% on a year-over-year basis. Research analysts forecast that Medtronic will post 5.44 earnings per share for the current fiscal year.

Medtronic Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Friday, July 12th. Stockholders of record on Friday, June 28th were given a dividend of $0.70 per share. This is a boost from Medtronic’s previous quarterly dividend of $0.69. The ex-dividend date was Friday, June 28th. This represents a $2.80 annualized dividend and a dividend yield of 3.59%. Medtronic’s payout ratio is currently 101.82%.

Wall Street Analyst Weigh In

MDT has been the subject of several analyst reports. UBS Group lifted their price target on shares of Medtronic from $75.00 to $76.00 and gave the stock a sell rating in a research report on Friday, May 24th. Truist Financial reduced their price target on shares of Medtronic from $90.00 to $88.00 and set a hold rating for the company in a report on Friday, May 24th. Needham & Company LLC reiterated a hold rating on shares of Medtronic in a report on Friday, May 24th. The Goldman Sachs Group started coverage on shares of Medtronic in a report on Thursday, May 30th. They issued a sell rating and a $83.00 price target for the company. Finally, Royal Bank of Canada reiterated a sector perform rating and issued a $92.00 price target on shares of Medtronic in a report on Wednesday, June 5th. Two research analysts have rated the stock with a sell rating, six have issued a hold rating and five have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of Hold and a consensus price target of $91.09.

Insider Transactions at Medtronic

In other Medtronic news, CEO Geoffrey Martha sold 19,113 shares of the company’s stock in a transaction on Friday, June 7th. The shares were sold at an average price of $83.77, for a total transaction of $1,601,096.01. Following the sale, the chief executive officer now directly owns 143,348 shares of the company’s stock, valued at $12,008,261.96. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 0.30% of the stock is currently owned by insiders.

Medtronic Company Profile

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.